On behalf of the Pulmonary Fibrosis Foundation
Published: March 22, 2022
Cough is a common symptom of interstitial lung disease (ILD) and negatively impacts health-related quality of life (QOL). Previous studies have shown that among patients with idiopathic pulmonary fibrosis, cough may predict progression of lung disease and perhaps even respiratory hospitalizations and mortality.
Does cough-specific QOL predict disease progression, respiratory hospitalization, lung transplantation, and death among patients with ILD?
Study Design and Methods
We analyzed data from the Pulmonary Fibrosis Foundation Registry, which comprises a multicenter population of well-characterized patients with ILD. We first examined associations between patient factors and baseline scores on the Leicester Cough Questionnaire (LCQ), a cough-specific QOL tool, using a proportional odds model. Next, we examined associations between baseline LCQ scores and patient-centered clinical outcomes, as well as pulmonary function parameters, using a univariate and multivariate proportional hazards model that was adjusted for clinically relevant variables, including measures of disease severity.
One thousand four hundred forty-seven patients with ILD were included in our study. In the multivariate proportional odds model, we found that the following patient factors were associated with worse cough-specific QOL: younger age, diagnosis of “other ILD,” gastroesophageal reflux disease, and lower FVC % predicted. Multivariate Cox regression models, adjusting for several variables including baseline disease severity, showed that a 1-point decrease in LCQ score (indicating lower cough-specific QOL) was associated with a 6.5% higher risk of respiratory-related hospitalization (hazard ratio [HR], 1.065; 95% CI, 1.025-1.107), a 7.4% higher risk of death (HR, 1.074; 95% CI, 1.020-1.130), and an 8.7% higher risk of lung transplantation (HR, 1.087; 95% CI, 1.022-1.156).
Among a large population of well-characterized patients with ILD, cough-specific QOL was associated independently with respiratory hospitalization, death, and lung transplantation.
ACE (angiotensin-converting enzyme), Dlco (diffusing capacity of the lungs for carbon monoxide), GERD (gastroesophageal reflux disease), HP (hypersensitivity pneumonitis), HR (hazard ratio), IIP (idiopathic interstitial pneumonia), ILD (interstitial lung disease), IPF (idiopathic pulmonary fibrosis), LCQ (Leicester Cough Questionnaire), PFT (pulmonary function test), PRO (patient-reported outcome), PFFR (Pulmonary Fibrosis Foundation Registry), QOL (quality of life)